Pulmocide

Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocides innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a...

Severe respiratory diseases,inhaled therapeutics,pulmonary aspergillosis,pharmaceuticals,acute and chronic lung infections,and pulmonary

Pulmocide operates in the Biotechnology research industry.

Pulmocide's revenue is 1m - 10m

Pulmocide has 11 - 50 employees.